The stock may react positively to the clinical data and financing, but the widening loss could pressure shares; monitor upcoming topline data from Phase 2 Seabreeze STAT studies in mid-2026 for next major catalyst.
Price Chart
Executive Summary
Connect Biopharma reported full-year 2025 financial results with a net loss of $55.5 million ($1.00 per share), driven by increased R&D and G&A expenses. The company highlighted positive Phase 1 and Phase 3 clinical data for rademikibart, ongoing enrollment in Phase 2 studies, and a $20.2 million private placement to extend cash runway into mid-2027.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $55.5 million, or $1.00 per share, compared to $15.6 million, or $0.28 per share, in 2024.
- R&D expense increased to $37.8 million in 2025 from $29.3 million in 2024 due to Phase 2 Seabreeze STAT studies.
- G&A expense rose to $20.3 million in 2025 from $19.2 million in 2024 as the company shifts to a more U.S.-centric structure.
- Cash, cash equivalents, and short-term investments were $44.3 million as of December 31, 2025.
- Entered into a $20.2 million private placement with institutional investors, expected to close March 31, 2026, extending cash runway into the second half of 2027.
- Positive topline data from Phase 1 IV study of rademikibart in asthma/COPD patients showed rapid FEV1 improvement.
- Phase 3 study results in atopic dermatitis (AD) showed rapid, durable efficacy and safety similar to placebo.
Financial Impact
Net loss widened to $55.5 million in 2025 from $15.6 million in 2024, with EPS of $-1.00 vs $-0.28. The $20.2 million private placement provides additional runway.
Risk Factors
- Widening net loss and continued negative cash flows from operations.
- Reliance on future clinical trial outcomes and regulatory approvals.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001835268-26-000012 |
| Document: cntb-20260331.htm | 0001835268-26-000012 |
| Document: 0001835268-26-000012-index-headers.html | 0001835268-26-000012 |
| Document: 0001835268-26-000012-index.html | 0001835268-26-000012 |
| Document: 0001835268-26-000012.txt | 0001835268-26-000012 |
| 8-K Data (Synthetic) | 0001835268-26-000012 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | SC 13G | $0.9450 $0.9090 | ▼ −3.81% | ▼ −2.83% | $0.8302 (−12.15%) |
Sep 30, 2026 27d ago | 8-K | $1.10 $0.9450 | ▼ −14.09% | ▼ −16.00% | $0.8302 (−24.53%) |
Sep 30, 2026 27d ago | Press Release | $1.10 $0.9447 | ▼ −14.12% | ▼ −16.03% | $0.8302 (−24.53%) |
Sep 15, 2026 6w ago | 8-K | $1.17 $1.28 | ▲ +9.40% | ▲ +8.58% | $0.8302 (−29.04%) |
May 12, 2026 24w ago | 8-K | $2.68 $2.38 | ▼ −11.19% | ▼ −11.27% | $0.8302 (−69.02%) |
May 12, 2026 24w ago | Press Release | $2.68 $2.38 | ▲ +11.19% | ▲ +11.27% | $0.8302 (+69.02%) |
Apr 23, 2026 26w ago | 8-K | $2.52 $2.53 | ▲ +0.40% | ▼ −1.08% | $0.8302 (−67.06%) |
Mar 31, 2026 29w ago | 8-K | $2.72 $2.78 | ▲ +2.21% | ▼ −1.56% | $0.8302 (−69.48%) |
Mar 30, 2026 30w ago | Press Release | $2.90 $2.82 | ▼ −2.76% | ▼ −7.06% | $0.8302 (−71.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers